Skip to main content

Hismanal Side Effects

Generic name: astemizole

Note: This document contains side effect information about astemizole. Some of the dosage forms listed on this page may not apply to the brand name Hismanal.

Applies to astemizole: oral tablet


Astemizole and its predominant metabolite, desmethylastemizole, have been associated with prolongation of the QT interval. Most cardiovascular events related to astemizole (the active ingredient contained in Hismanal) occur in patients with higher than normal astemizole serum concentrations (either due to ingesting more than the recommended dose of 10 mg once daily or due to reduced elimination) or in patients at risk for cardiac events. Macrolide antibiotic and azole antifungal agents may inhibit the metabolism of astemizole, resulting in QT interval prolongation. Patients with liver dysfunction are also at risk due to decreased metabolism of the drug. Other predisposing factors include congenital forms of QT interval prolongation, coronary artery disease, and electrolyte disorders including hypokalemia and hypomagnesemia. Although rare, arrhythmias have been reported in patients on recommended doses without apparent risk factors[Ref]

Cardiovascular system adverse effects have been associated with the use of astemizole. Adverse effects reported include dizziness, syncopal episodes, palpitations, ventricular arrhythmias (including torsades de pointes), cardiac arrest, and cardiac death.[Ref]

Nervous system

Nervous system adverse effects associated with astemizole (the active ingredient contained in Hismanal) are rare. Headaches may occur in approximately 7% of treated patients. Astemizole has not been shown to cause significant drowsiness, sedation, or impair psychomotor skills. Increased appetite and weight gain has been reported in approximately 4% of patients.[Ref]


Gastrointestinal effects of astemizole (the active ingredient contained in Hismanal) are rare and include nausea and dry mouth.[Ref]


Rare cases of anaphylaxis, including anaphylactic shock, have been reported.[Ref]

More about Hismanal (astemizole)

Related treatment guides


1. Scheman C, Nightingale SL, Kessler DA, et al. "New boxed warnings added for seldane, hismanal." FDA Med Bull 22 (1992): 2-3

2. Kemp JP "Antihistamines--is there anything safe to prescribe?" Ann Allergy 69 (1992): 276-80

3. "Safety of terfenadine and astemizole." Med Lett Drugs Ther 34 (1992): 9-10

4. "Product Information. Hismanal (astemizole)." Janssen Pharmaceuticals (2002):

5. Craft TM "Torsade de pointes after astemizole overdose." Br Med J 292 (1986): 660

6. Giddins NG, Simons KJ, Simons FE, Kesselman MS, Pelech AN "Astemizole-induced torsade de pointes." Lancet 2 (1988): 624

7. Colin-Jones D, Boothman-Burrell D, Snook J, Watkins J "Torsade de pointes ventricular tachycardia associated with astemizole overdose." Br J Clin Pract 42 (1988): 257-9

8. Sakemi H, VanNatta B "Torsade de pointes induced by astemizole in a patient with prolongation of the QT interval." Am Heart J 125 (1993): 1436-8

9. Saviuc P, Dixmerias F, Danel V "Prolonged QT interval and torsade de pointes following astemizole overdose." J Toxicol Clin Toxicol 31 (1993): 121-5

10. Broadhurst P, Nathan AW "Cardiac arrest in a young woman with the long QT syndrome and concomitant astemizole ingestion." Br Heart J 70 (1993): 469-70

11. Blake K, Goss JE, Ramo BW "Torsades de pointes associated with astemizole (hismanal) therapy." Arch Intern Med 153 (1993): 2705

12. Adlakha A, Meloy TD, Stanton MS, Rao KA, Vermaansil B "Torsades de pointes ventricular tachycardia associated with overdose of astemizole." Mayo Clin Proc 69 (1994): 589-93

13. Smith SJ "Cardiovascular toxicity of antihistamines." Otolaryngol Head Neck Surg 111 Suppl (1994): 348-54

14. Guinosso PJ, Stupienski RF, Jurkiewicz NK, Wallace AA, Salata JJ, Lynch JJ "Cardiac electrophysiological actions of the histamine h-1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine." Circ Res 76 (1995): 110-9

15. Berul CI, Morad M "Regulation of potassium channels by nonsedating antihistamines." Circulation 91 (1995): 2220-5

16. Horsmans Y, Desager JP "Pharmacokinetic pharmacodynamic relationships of h-1-antihistamines." Clin Pharmacokinet 28 (1995): 419-32

17. Heidemann SM, Sarnaik AP "Arrhythmias after astemizole overdose." Pediatr Emerg Care 12 (1996): 102-4

18. Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52

19. Hoon TJ, Zhou ZF, January CT, Vorperian VR, Mohammad S, Studenik C "Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole." J Am Coll Cardiol 28 (1996): 1556-61

20. Avery GS, Brogden RN, Heel RC, Speight TM, Richards DM "Astemizole. A review of its pharmacodynamic properties and therapeutic efficacy." Drugs 28 (1984): 38-61

21. Krause LB, Shuster S "A comparison of astemizole and chlorpheniramine in dermographic urticaria." Br J Dermatol 112 (1985): 447-53

22. Bunnag C, Jareoncharsri P, Wong EC "A double-blind comparison of nasal budesonide and oral astemizole for the treatment of perennial rhinitis." Allergy 47 (1992): 313-7

23. Fraser TG, Simons FER, Simons KJ, Reggin JD "Comparison of the central nervous system effects produced by six h-1-receptor antagonists." Clin Exp Allergy 26 (1996): 1092-7

24. Dolovich J, Juniper EF, White J "Efficacy of continuous treatment with astemizole (Hismanal) and terfenadine (Seldane) in ragweed pollen-induced rhinoconjunctivitis." J Allergy Clin Immunol 82 (1988): 670-5

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.